Lantis Laser Signs Letter of Intent to Merge With Perio-Imaging Inc.

The combined company expects to generate higher overall revenues, which will now include a substantial recurring component. In total, managementbelieves that the combined company will represent a significantly more attractive investment opportunity, in terms of its technological and financial characteristics as well as the large market its products pipeline addresses.

On the basis of a merged company, management will seek investment options to raise the necessary capital to advance its product portfolio to commercialization.

Lantis Laser has licensed rights to optical coherence tomography ("OCT") and near infrared transillumination imaging technology for applications in the dental field. Its product focus is on detection of early, later and hidden decay and microstructural defects in teeth. Both modalities are light-based and therefore do not emit potentially harmful radiation. OCT has been successfully used in ophthalmology for many years and recently FDA clearance for cardiovascular imaging was granted to a Lantis Laser licensor.

Perio Imaging Inc. has developed a novel ultrasound periodontal imaging device, the Perio-Imager, for the early detection of periodontal disease and establishing a patient's periodontal condition. Periodontal disease is not only a major cause of tooth loss but has been linked to other systemic diseases such as diabetes, cardiovascular disease and pancreatic cancer. Detecting, quantifying and tracking a patient's periodontal condition are important aspects of modern dentistry and disease prevention. The Perio-Imager provides a quick, easy to use, inexpensive and accurate method of detecting early stage periodontal disease as compared to the traditional sharp pointed manual probe. Management believes that this provides tremendous revenue generating potential for the dental office by enabling general dentists to treat patients who would ordinarily be referred to a periodontist. The Perio-Imager is intended to be a non-contact, painless, accurate modality that provides an objective, accurate measurement of periodontal pockets depths, the early sign of periodontal disease.

The Perio-Imager is in the final stages of development and would be offered at a relatively modest price point to the dentist, currently estimated at less than $3,000, making it, in management's view, affordable for all dental offices. Perio's revenue model also incorporates a significant recurring revenue component with a usage fee for each patient exam.

Stan Baron, President and CEO of Lantis, said, "We firmly believe that there are strong synergies between the respective companies' technologies which could be sold in an integrated chairside platform or as standalone devices. With this combination, we expect that the new merged company would become a key leader not only in the area of early detection of decay but also of periodontal disease. Despite advances in dental health, these diseases are still very prevalent and trends towards early detection and minimally invasive treatment require a level of diagnostic capabilities not currently available." He went on to add that the new company will also benefit from synergies in senior management, operations and marketing, as well as access to a highly regarded Dental Advisory Board.

"We are excited about the merger with Lantis as this creates a company with what we believe are the best solutions to enhance the dentists' ability to make earlier, more accurate diagnoses, better treatment plans and enhanced outcomes. Most critically, we believe that the combined company will offer a very attractive business model with a diverse set of technologies and quicker time to market," said Barry J. Berman, President and CEO of Perio-Imaging.